Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia
14 févr. 2023 06h30 HE
|
Verve Therapeutics
BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...
Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 16h05 HE
|
Verve Therapeutics
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics to Participate in Upcoming Investor Conferences
11 nov. 2022 06h30 HE
|
Verve Therapeutics
BOSTON, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
07 nov. 2022 06h30 HE
|
Verve Therapeutics
VERVE-101 Investigational New Drug Application Placed on Hold by U.S. Food and Drug Administration Dosing Completed in First Dose Cohort of the heart-1 Clinical Trial of VERVE-101 in Patients with...
Verve Therapeutics Announces Publication of VERVE-101 Preclinical Data in Circulation and Presentations at the American Heart Association Annual Meeting
31 oct. 2022 07h00 HE
|
Verve Therapeutics
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...
Verve Therapeutics to Participate in Upcoming Investor Conferences
22 sept. 2022 06h30 HE
|
Verve Therapeutics
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course...
Verve Therapeutics Announces Clearance of Clinical Trial Authorisation Application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
21 sept. 2022 06h30 HE
|
Verve Therapeutics
CAMBRIDGE, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with...
Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 Congress
22 août 2022 06h30 HE
|
Verve Therapeutics
CAMBRIDGE, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with...
Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results
09 août 2022 06h30 HE
|
Verve Therapeutics
Over $300 Million in Capital Added to Balance Sheet, Supporting an Operating Runway into Second Half of 2025 Patient Dosing Underway with Lead Candidate, VERVE-101, for Treatment of Heterozygous...
Verve Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
25 juil. 2022 16h01 HE
|
Verve Therapeutics
CAMBRIDGE, Mass., July 25, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with...